Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 33 entries
View as:

Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03025867 Org: User:
Start: - End: - Due: -

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05751629 Org: User:
Start: 11/15/18 End: 04/01/22 Due: 04/01/23

MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)

Phase: N/A Priority: Normal
NCT ID: NCT01227941 Org: User:
Start: 11/30/10 End: 09/30/11 Due: 09/30/12

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02657889 Org: User:
Start: 04/15/16 End: 09/17/21 Due: 09/17/22

An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02434861 Org: User:
Start: 05/31/15 End: 08/31/15 Due: 08/31/16

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Phase: N/A Priority: Normal
NCT ID: NCT03307785 Org: User:
Start: 10/12/17 End: 08/30/24 Due: 08/30/25

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01847274 Org: User:
Start: 06/21/13 End: 12/26/21 Due: 12/26/22

A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT02048488 Org: User:
Start: 10/31/12 End: 06/30/18 Due: 06/30/19

An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant

Phase: N/A Priority: Normal
NCT ID: NCT02285647 Org: User:
Start: 09/30/14 End: 05/31/15 Due: 05/31/16

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT03326193 Org: User:
Start: 12/12/17 End: 07/12/24 Due: 07/12/25

A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

Phase: N/A Priority: Normal
NCT ID: NCT02354586 Org: User:
Start: 03/23/15 End: 08/23/21 Due: 08/23/22

A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02382666 Org: User:
Start: 01/31/15 End: 08/31/15 Due: 08/31/16

A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)

Phase: N/A Priority: Normal
NCT ID: NCT01110603 Org: User:
Start: 07/31/10 End: 07/31/11 Due: 07/31/12

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02655016 Org: User:
Start: 07/11/16 End: 09/30/25 Due: 09/30/26

A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03574779 Org: User:
Start: 11/15/18 End: 03/31/25 Due: 03/31/26

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT01905592 Org: User:
Start: 02/25/14 End: 10/26/21 Due: 10/26/22

Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT01500226 Org: User:
Start: 02/29/12 End: 02/28/14 Due: 02/28/15

A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)

Phase: N/A Priority: Normal
NCT ID: NCT01244009 Org: User:
Start: 12/31/10 End: 08/31/13 Due: 08/31/14

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Phase: N/A Priority: Normal
NCT ID: NCT02817633 Org: User:
Start: 07/08/16 End: 04/27/27 Due: 04/27/28

Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule

Phase: N/A Priority: Normal
NCT ID: NCT03329001 Org: User:
Start: 12/04/17 End: 06/15/23 Due: 06/15/24

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02715284 Org: User:
Start: 03/07/16 End: 10/27/27 Due: 10/27/28

A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)

Phase: N/A Priority: Normal
NCT ID: NCT00749502 Org: User:
Start: 09/30/08 End: 06/30/13 Due: 06/30/14

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

Phase: N/A Priority: Normal
NCT ID: NCT03308942 Org: User:
Start: 09/29/17 End: 08/31/21 Due: 08/31/22

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03981796 Org: User:
Start: 07/15/19 End: 11/26/26 Due: 11/26/27

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03602859 Org: User:
Start: 10/11/18 End: 06/22/26 Due: 06/22/27